 NEW YORK, Oct. 13, 2021 GLOBE NEWSWIRE -- GBS Inc. Nasdaq: GBS, a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has filed a Pre-Submission package with the United States US Food and Drug Administration FDA. The purpose of this pre-submission is to confirm with the FDA that GBS is following the proper steps to conduct the clinical studies enabling it to develop the glucose biosensor according to the FDA regulatory standards. 